Brief: Mabion Gets Permission To Run Bridging Clinical Trial Of MabionCD20 Drug in Georgia
14/10/2021 11:22
Oct 14 (Reuters) - Mabion SA MABP.WA :
* GETS PERMISSION FROM GEORGIA'S HEAD OF MEDICINES AUTHORITY
TO
RUN BRIDGING CLINICAL TRIAL OF MABIONCD20 DRUG FOR RHEUMATOID
ARTHRITIS PATIENTS
Source text for Eikon: ID:nEM5lb5Qxa
Further company coverage: MABP.WA
(Reporting by Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com;))
Recent news on Mabion SA
See all newsBrief: Mabion Signs Annex To Extend Production Agreement With Novavax To End of 2029
Brief: Mabion Signs Deal With Oddifact Sas On Preparing Mabioncd20 For FDA Consultation
Brief: Mabion Q1 Net Loss 9.7 Million Zlotys
Brief: Mabion Signs LoI With Oddifact On Use Of MabionCD20 Drug For Orphan Diseases
Brief: Mabion FY Net Loss 62.6 Million Zlotys